Balducci, Estelle

Brunet, Corinne

Brégigeon, Sylvie

Dignat-George, Françoise

Dukan, Patrick

Faucher, Olivia

Martin, Isabelle Poizot

Menard, Amélie

Obry, Véronique

Ritleng, Anne-Suzel

English

PubMed

Amélie Menard

Corinne Brunet

Véronique Obry

Patrick Dukan

Sylvie Brégigeon

Olivia Faucher

Estelle Balducci

Anne-Suzel Ritleng

Françoise Dignat-George

Isabelle Poizot Martin

Crossref

POSTER PRESENTATION Open AccessChanges in immune activation in the T Cellcompartments of HIV HCV coinfected patientsduring PEG IFN RBV treatmentAmélie Menard*, Corinne Brunet, Véronique Obry, Patrick Dukan, Sylvie Brégigeon, Olivia Faucher, Estelle Balducci,Anne-Suzel Ritleng, Françoise Dignat-George, Isabelle Poizot MartinFrom 17th International Symposium on HIV and Emerging Infectious Diseases (ISHEID)Marseille, France. 23-25 May 2012Chronic activation of CD8 T-cell compartment is criticalduring HCV-HIV-1 coinfection. The objective of thisstudy was to evaluate the impact of pegylated-interferon(PEG-IFN) in combination with ribavirin (RBV) onimmune activation in HCV-HIV-coinfected patients.T cell phenotype (CD8+CD38+,CD8+DR+) was quan-tified using flow cytometry analysis,. Measurementswere performed at day one of treatment (Baseline, BL),then at week (W)12,W24,W48 and W24 post-treatment.HVC viral load was measured using a PCR (COBASTaqMan 48; Roche), exhibiting a limit of detection at12IU/ml. Statistical analysis was performed with SPSS 17.0.11 pts (64% of males; median age 47.4 [45.1-51]) witha median follow up for HCV infection of 14.7y [11.7;19.1]) were evaluated. All were treated for HIV infection(PI- based regimen: 63.6%) with an HIV-VL < 40copies/ml. Median CD4 and CD8 T cells count at BL was 886/mm3 [671; 1008] and 825/mm3 [530; 1843], respec-tively. HCV genotype was 1 for 63.6%, 3 in 27.3% and 4in one pt. HCV VL at BL was 5.9 [4.6; 6.7] (log UI/ml).Up to now, 2 pts stopped HCV treatment at W2 andW4, 9 pts have reached W24, and 5 of them arebetween W24 and W48. The results at W12 and W24are presented in the table. We observed a significantdecrease of the number of circulating total lymphocytesand CD4T cells in absolute value (p=0.008), but a signif-icant increase in the percentage of CD4+ T-cells and asignificant decrease in the percentage of CD8+ T cellsat W24. HCV VL was negative for all of them.These preliminary results show that the immune systemhyperactivation driving by HCV disease can be reducedwith a control of HCV replication. However, we observeda discrepancy in the evolution of CD8+CD38+ and CD8+DR+ expression at W12 which remains at W24.Theseresults have to be confirmed with the next measurementperformed at W48 and W24 post treatment.Published: 25 May 2012doi:10.1186/1742-4690-9-S1-P56Cite this article as: Menard et al.: Changes in immune activation in theT Cell compartments of HIV HCV coinfected patients during PEG IFNRBV treatment. Retrovirology 2012 9(Suppl 1):P56.Haematology-Aids Unit Hôpital Sainte-Marguerite, Marseille, FranceTable 1BL W12 p W24 pCD4+ T Cell (%) 27.0 [24.5; 37.1] 37.5 [26.8; 46.0] 0.008 43.0 [30.5; 47.3] 0.011CD8+ T Cell (%) 46.0 [30.4; 51.0] 43.2 [25.9; 49.7] 0.110 37.4 [26.5; 46.9] 0.028DR+CD8+ T Cell (%) 11.0 [6.4; 19.5] 5.2 [2.8; 9.9] 0.017 2.4 [1.4; 7.4] 0.008CD38+CD8+ T Cell (%) 14.7 [6.8; 21.5] 43.2 [28.9; 48.9] 0.008 36.2 [15.7; 47.1] 0.015Menard et al. Retrovirology 2012, 9(Suppl 1):P56http://www.retrovirology.com/content/9/S1/P56© 2012 Menard et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative CommonsAttribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction inany medium, provided the original work is properly cited.

Retrovirology

Changes in immune activation in the T Cell compartments of HIV HCV coinfected patients during PEG IFN RBV treatment

Springer - Publisher Connector

POSTER PRESENTATION Open Access
Changes in immune activation in the T Cell
compartments of HIV HCV coinfected patients
during PEG IFN RBV treatment
Amélie Menard*, Corinne Brunet, Véronique Obry, Patrick Dukan, Sylvie Brégigeon, Olivia Faucher, Estelle Balducci,
Anne-Suzel Ritleng, Françoise Dignat-George, Isabelle Poizot Martin
From 17th International Symposium on HIV and Emerging Infectious Diseases (ISHEID)
Marseille, France. 23-25 May 2012
Chronic activation of CD8 T-cell compartment is critical
during HCV-HIV-1 coinfection. The objective of this
study was to evaluate the impact of pegylated-interferon
(PEG-IFN) in combination with ribavirin (RBV) on
immune activation in HCV-HIV-coinfected patients.
T cell phenotype (CD8+CD38+,CD8+DR+) was quan-
tified using flow cytometry analysis,. Measurements
were performed at day one of treatment (Baseline, BL),
then at week (W)12,W24,W48 and W24 post-treatment.
HVC viral load was measured using a PCR (COBAS
TaqMan 48; Roche), exhibiting a limit of detection at12
IU/ml. Statistical analysis was performed with SPSS 17.0.
11 pts (64% of males; median age 47.4 [45.1-51]) with
a median follow up for HCV infection of 14.7y [11.7;
19.1]) were evaluated. All were treated for HIV infection
(PI- based regimen: 63.6%) with an HIV-VL < 40copies/
ml. Median CD4 and CD8 T cells count at BL was 886/
mm3 [671; 1008] and 825/mm3 [530; 1843], respec-
tively. HCV genotype was 1 for 63.6%, 3 in 27.3% and 4
in one pt. HCV VL at BL was 5.9 [4.6; 6.7] (log UI/ml).
Up to now, 2 pts stopped HCV treatment at W2 and
W4, 9 pts have reached W24, and 5 of them are
between W24 and W48. The results at W12 and W24
are presented in the table. We observed a significant
decrease of the number of circulating total lymphocytes
and CD4T cells in absolute value (p=0.008), but a signif-
icant increase in the percentage of CD4+ T-cells and a
significant decrease in the percentage of CD8+ T cells
at W24. HCV VL was negative for all of them.
These preliminary results show that the immune system
hyperactivation driving by HCV disease can be reduced
with a control of HCV replication. However, we observed
a discrepancy in the evolution of CD8+CD38+ and CD8
+DR+ expression at W12 which remains at W24.These
results have to be confirmed with the next measurement
performed at W48 and W24 post treatment.
Published: 25 May 2012
doi:10.1186/1742-4690-9-S1-P56
Cite this article as: Menard et al.: Changes in immune activation in the
T Cell compartments of HIV HCV coinfected patients during PEG IFN
RBV treatment. Retrovirology 2012 9(Suppl 1):P56.
Haematology-Aids Unit Hôpital Sainte-Marguerite, Marseille, France
Table 1
BL W12 p W24 p
CD4+ T Cell (%) 27.0 [24.5; 37.1] 37.5 [26.8; 46.0] 0.008 43.0 [30.5; 47.3] 0.011
CD8+ T Cell (%) 46.0 [30.4; 51.0] 43.2 [25.9; 49.7] 0.110 37.4 [26.5; 46.9] 0.028
DR+CD8+ T Cell (%) 11.0 [6.4; 19.5] 5.2 [2.8; 9.9] 0.017 2.4 [1.4; 7.4] 0.008
CD38+CD8+ T Cell (%) 14.7 [6.8; 21.5] 43.2 [28.9; 48.9] 0.008 36.2 [15.7; 47.1] 0.015
Menard et al. Retrovirology 2012, 9(Suppl 1):P56
http://www.retrovirology.com/content/9/S1/P56
© 2012 Menard et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.


Isabelle Martin

Menard Amélie

Brunet Corinne

Obry Véronique

Dukan Patrick

Brégigeon Sylvie

Faucher Olivia

Balducci Estelle

Ritleng Anne-Suzel

Dignat-George Françoise

Martin Isabelle

Directory of Open Access Journals

https://retrovirology.biomedcentral.com/track/pdf/10.1186/1742-4690-9-S1-P56?site=retrovirology.biomedcentral.com

Changes in immune activation in the T Cell compartments of HIV HCV coinfected patients during PEG IFN RBV treatment

Abstract

Similar works

Full text

Available Versions

Crossref

Springer - Publisher Connector

Springer - Publisher Connector

Directory of Open Access Journals